-
Mashup Score: 4Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera - 7 hour(s) ago
Key PointsTreatment with ruxolitinib and interferon alfa-2a is well tolerated with anemia as the main cause for dose reduction.Treatment with ruxolitinib a
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 13Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia - 1 month(s) ago
Key PointsThe establishment of a clinical network led to significant and lasting advancements in the treatment outcomes of APL over a span of 15 years.The
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 18Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis - 1 month(s) ago
Key PointsLuspatercept improved anemia in patients with MF with/without transfusion dependence, particularly those receiving ruxolitinib.After 3 years of m
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 23Metformin use and risk of myeloproliferative neoplasms: a Danish population–based case-control study - 2 month(s) ago
Key PointsMetformin use was associated with a significant decrease in risk of MPN, with the largest effect observed for the ET and PV subtypes.A dose-respo
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 35Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial - 2 month(s) ago
TO THE EDITOR:
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 91
Key PointsIn NPM1 AML, FLT3-ITD, DNMT3A, WT1, and non-ABD NPM1mut increase MRD positivity and (except FLT3-ITD) relapse from MRD negativity.MRD negativity
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 13Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome - 2 month(s) ago
Key PointsIvosidenib resulted in a CR rate of 38.9% and an OR rate of 83.3% in mIDH1 R/R MDS; median duration of response was not reached.Median OS in this
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia - 5 month(s) ago
FF-10101 is an irreversible inhibitor of FLT3 active against most types of FLT3 activating mutations.FF-10101 induced responses in patients who had progres
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials - 5 month(s) ago
Enasidenib treatment may be associated with DS in patients with AML, yet diagnosis of DS is challenging because of nonspecific symptoms.IDH inhibition-asso
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial - 6 month(s) ago
There was no clear survival benefit for guadecitabine over standard-of-care in patients with relapsed/refractory AML.Guadecitabine produced higher clinical
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
Treatment with ruxolitinib and interferon alfa-2a is well tolerated with anemia as the main cause for dose reduction. https://t.co/o8Qvj2o20D #clinicaltrialsandobservations #myeloidneoplasia https://t.co/lMOhadmwES